Rare cancers, although less frequent, pose special problems in diagnosis, management, and research because they have sparse data and heterogeneous tumor biology. The session "Rare Cancer Updates" is dedicated to recent developments, clinical observations, and new therapies for these rare malignancies.".
Rare cancer updates involve new information on molecular profiling, targeted agents, immunotherapeutics, and combination regimens. Genomic and proteomic studies enable clinicians to recognize actionable mutations, directing individualized treatment strategies even within the context of sparse clinical guidelines. Novel clinical trials and multicenter research networks are critical to collect data and assess new interventions in rare cancer patients.
The session also emphasizes multidisciplinary treatment, stressing coordinated effort among oncologists, surgeons, radiologists, pathologists, and researchers to deliver optimal care. New therapies, including CAR T-cell therapy, targeted inhibitors, and precision immunotherapy, are being investigated to enhance outcomes in rare tumor histotypes. Registry-based research and case studies give useful insights to guide clinical decision-making and patient care.
Participants will learn about the new research, clinical applications, and therapeutic developments in rare cancers. This session highlights how innovative science, personalized approaches, and cooperative efforts are revolutionizing care, enhancing survival, and providing new hope for rare malignancy patients.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
